North America Companion Diagnostics Market Industry Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Companion diagnostics are laboratory tests used to identify patients most likely to benefit from specific targeted therapies, primarily in oncology. The North American market has grown rapidly as regulatory agencies and healthcare providers prioritize personalized treatment pathways, with diagnostics now routinely co-developed alongside new drugs.

• •Companion diagnostics are required for over 20% of newly approved oncology drugs in the U.S. since 2015.
• •The market is tightly linked to the growth of the broader in vitro diagnostics sector, which reached $109.06 billion globally in 2025.
• •Over 70% of companion diagnostic applications in North America are for cancer indications, particularly solid tumors.

The expansion of this market is primarily driven by regulatory incentives, increased clinical adoption of genomic profiling, and the rising volume of targeted therapies entering the pipeline. Payors are increasingly requiring diagnostic confirmation before approving high-cost biologics, reinforcing the economic value of companion tests.

• •FDA mandates companion diagnostics for approximately 1 in 5 new drug approvals, accelerating co-development.
• •Advances in next-generation sequencing and AI-driven data analysis have reduced test turnaround times and costs.
• •Rising cancer incidence and aging populations in North America are increasing demand for precision diagnostics.

The market is segmented by technology platform, application, and geography, with the U.S. accounting for over 85% of North American revenue due to its advanced healthcare infrastructure and robust clinical trial ecosystem. Molecular diagnostics dominate the segment, followed by immunohistochemistry and next-generation sequencing.

• •Molecular diagnostics hold the largest market share, driven by NGS and PCR-based platforms for gene mutation detection.
• •The U.S. leads in adoption, while Canada and Mexico show slower but steady growth, primarily in academic medical centers.
• •Oncology applications represent more than 80% of diagnostic volume, with emerging use in autoimmune and neurodegenerative diseases.

Who are the notable companies in the industry?

The market exhibits moderate consolidation, with a mix of integrated diagnostic manufacturers and specialized players focused on niche technologies. The dominant technology routes involve nucleic acid amplification, immunoassay platforms, and next-generation sequencing, with increasing integration of digital pathology and AI analytics. Capacity is heavily concentrated in the U.S., particularly in regions with strong biotech clusters such as the Northeast and California.

• •The industry is moderately consolidated, with a few large players dominating volume and regulatory pathways, while smaller firms focus on innovation in niche biomarkers.
• •Most producers are vertically integrated, combining test development with assay instrumentation and data analysis software.
• •Technology routes are dominated by PCR, NGS, and IHC, with emerging adoption of proteomic and multi-omics platforms.

What are the recent trends and outlook?

The future of the North American companion diagnostics market will be shaped by the convergence of multi-omics testing, real-world data integration, and decentralized testing models. Expansion into non-oncology indications and the rise of point-of-care molecular platforms are expected to broaden market reach beyond traditional hospital labs.

• •Point-of-care molecular diagnostics, growing at 11.37% CAGR, are beginning to enable rapid companion testing in community clinics.
• •Regulatory agencies are encouraging liquid biopsy adoption as a less invasive alternative to tissue-based testing.
• •By 2030, over 40% of new drug-labeling will require a companion diagnostic, with increasing emphasis on pan-cancer and pharmacogenomic biomarkers.